Brief: Genprex Collaborators Report Positive Preclinical Data On The Use Of Reqorsa Gene Therapy
30/04/2025 13:42
April 30 (Reuters) - Genprex Inc GNPX.O: GENPREX COLLABORATORS REPORT POSITIVE PRECLINICAL DATA ON THE USE OF REQORSA® GENE THERAPY FOR THE TREATMENT OF RAS INHIBITOR RESISTANT LUNG CANCER AT THE 2025 AACR ANNUAL MEETING Source text: ID:nPn81HrV3a Further company coverage: GNPX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Genprex
See all newsBrief: Genprex Announces Collaboration With Roche Diagnostics For Biomarker Assay Validation Studies
NASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
Brief: Genprex Announces Ip Australia's Intent To Grant Patent For Reqorsa® Gene Therapy